Recurrent Pregnancy Loss, Plasminogen Activator Inhibitor-1 (-675) 4G/5G Polymorphism and Antiphospholipid Antibodies in Czech Women
Version of Record online: 27 FEB 2013
© 2013 John Wiley & Sons Ltd
American Journal of Reproductive Immunology
Volume 70, Issue 1, pages 54–58, July 2013
How to Cite
Recurrent pregnancy loss, plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and antiphospholipid antibodies in Czech women. Am J Reprod Immunol 2013; 70: 54–58., , , , , , .
- Issue online: 11 JUN 2013
- Version of Record online: 27 FEB 2013
- Manuscript Accepted: 24 JAN 2013
- Manuscript Received: 19 SEP 2012
- Ministry of Health of the Czech Republic. Grant Number: NR8917-3
- Ministry of Education of the Czech Republic. Grant Number: VZ MSM 002 162 0812
- Antiphospholipid antibodies;
- pregnancy loss;
This study compares the frequencies of plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and its relationship with eight antiphospholipid antibodies (aPLs) in serum of 157 patients with repeated pregnancy loss (RPL).
Method of study
PAI-1 (-675) 4G/5G polymorphism was determined using standard PCR-RFLP method. Enzyme-linked immunosorbent assay was used for the detection of aPLs against ph-serine, ph-ethanolamine, ph-inositol, ph-DL-glycerol, phosphatidic acid, annexin V, cardiolipin, and beta2-GPI. Allelic frequency and distribution of genotypes were calculated. The prevalence of the risk conferring 4G allele and 4G/4G homozygous genotype in patients and controls was compared, and the correlation between aPLs positivity and PAI-1 4G/4G genotype was tested by chi-square test.
Statistically highly significant correlation between RPL and PAI-1 (-675) 4G/4G genotype was found. No correlation between PAI-1 (-675) 4G/5G polymorphism and the presence of antiphospholipid antibodies in RPL patients was observed.
PAI-1 (-675) 4G/4G homozygous genotype increases the risk of RPL independently from the aPLs positivity.